Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Blue Sphere Teams With Stern Brothers
-
Provectus Biopharma (PVCT) Files Rights Offering Shelf with U.S. SEC for Existing Shareholders
-
Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders
-
Maxim Group Maintains Bullish View on Abeona Therapeutics (ABEO) After Safety Hurdle Cleared
-
CytoSorbents (CSTO) Bullish View Reiterated at Maxim Group on Commercial Launch of CytoSorb for Cardiac Surgery
-
Maxim Group Starts Nutanix (NTNX) at Buy
-
Maxim Group Starts Potbelly Corp (PBPB) at Hold
-
Maxim Group Starts DineEquity (DIN) at Buy
-
Abeona Therapeutics (ABEO): Visibility Improves Multiple, Raising PT - Maxim
-
bluebird bio (BLUE) PT Raised to $100 at Maxim Group
-
Stellar Acquisition III Inc. Announces Closing of Partial Over-Allotment Exercise in Connection With Its Initial Public Offering
-
Gladstone Investment Corporation Announces Closing of Offering of 2,300,000 Shares of its 6.25% Series D Cumulative Term Preferred Stock for Gross Proceeds of Approximately $57.5 million
-
Grom Holdings, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
-
Notable Analyst Rating Changes 9/22: (TI) (AMZN) (SEAS) Upgraded; (CBS) (FTI) (SYNT) Downgraded
-
bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim
-
Maxim Group Starts BeiGene, Ltd. (BGNE) at Buy
-
Maxim Group Starts Cellular Biomedicine Group (CBMG) at Buy
-
Maxim Group Starts CASI Pharmaceuticals (CASI) at Buy
-
Abeona Therapeutics (ABEO) PT Raised to $8 at Maxim Group
-
Streetinsider.com's Hot Lunchtime Reads 9/21: (LL) (RHT) (CUR) (TSLA)
-
Maxim Group Downgrades Mast Therapeutics (MSTX) to Hold Following Vepoloxamer Phase 3 Miss
-
SITO Mobile Announces Closing of Public Offering and Full Exercise of Overallotment Option
-
Gladstone Investment Corporation Prices Preferred Stock Offering
-
Workhorse Group (WKHS) PT Raised to $22 at Maxim Group; In Drivers Seat for $5B USPS Procurement
-
Gladstone Investment Corporation Launches New Term Preferred Stock Offering
-
SITO Mobile (SITO) Prices 2.67M Share Stock Offering for Proceeds of $10M
-
SITO Mobile Announces Pricing of $10 Million Underwritten Public Offering
-
SITO Mobile (SITO) to Offer Shares of Common Stock
-
SITO Mobile Announces Public Offering of Common Stock
-
Maxim Group LLC and Edison Group to Hold Inaugural Israel Day on September 14, 2016 in New York Over 19 Companies in Healthcare & Technology Sectors Expected to Present to Accredited Retail Invest
-
M I Acquisitions (MACQ) Prices 5M Unit IPO at $10/Unit
-
M I Acquisitions, Inc. Announces Pricing of $50,000,000 Initial Public Offering
-
Maxim Group Starts Xplore Technologies (XPLR) at Buy
-
Solar Senior Capital (SUNS) Prices 4M Common Stock Offering at $16.76/Share
-
Solar Senior Capital Ltd. Announces Pricing of Public Offering of Common Stock
-
Medigus (MDGS) Prices 1.28M Registered Direct Offering at $1.15/ADS
-
Medigus Announces Pricing of $1.47 Million Registered Direct Offering
-
Solar Senior Capital (SUNS) Announces 4M Share Common Stock Offering
-
Solar Senior Capital Ltd. Commences Public Offering of Common Stock
-
Intec Pharma to Participate in Upcoming September Conferences
-
Notable Analyst Rating Changes 9/7: (LGND) (GLPI) (DIN) Upgraded; (MNTA) (OLN) (TNXP) Downgraded
-
Pre-Open Stock Movers 09/07: (RTRX) (AAOI) (FRAN) (CMG) Higher; (SFM) (HDS) (CASY) Lower (more...)
-
Maxim Group Downgrades Momenta Pharmaceuticals (MNTA) to Sell
-
Maxim Group Starts Coherus Biosciences (CHRS) at Buy
-
Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering
-
Generic EpiPen Pricing Parity and Less than 1% Share Supports $10 Adamis (ADMP) Target Price - Maxim Group
-
Sophiris Bio Closes Underwritten Public Offering
-
Provectus Biopharma (PVCT) Prices $6M Conv. Preferred Stock Offering
-
Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million
-
Maxim Group Downgrades HP, Inc. (HPQ) to Hold


